Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 USD | 0.00% | -3.77% | -26.09% |
Apr. 30 | In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma | CI |
Apr. 10 | Top Premarket Gainers | MT |
- Stock Market
- Equities
- INAB Stock
- News IN8bio, Inc.
- Trading Ideas